Identification and analysis of survival‑associated ceRNA triplets in prostate adenocarcinoma

Li,Fan; Li,Hai; Hou,Yi

doi:10.3892/ol.2019.10752

Identification and analysis of survival‑associated ceRNA triplets in prostate adenocarcinoma

Authors:
- Fan Li
- Hai Li
- Yi Hou
View Affiliations

Affiliations: Department of Urology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: August 16, 2019 https://doi.org/10.3892/ol.2019.10752
Pages: 4040-4047
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate adenocarcinoma (PRAD) is one of the most common causes of cancer‑associated mortality worldwide. Recent evidence has emphasized the role of competitive endogenous RNAs (ceRNA) in prostate cancer. However, the current understanding of the roles that ceRNAs play in survival‑associated PRAD remains in its infancy. In the present study, a PRAD‑specific ceRNA network was constructed by integrating long non‑coding RNA (lncRNA)‑microRNA (miRNA)‑gene interactions using experimental and computational methods, as well as expression correlations from The Cancer Genome Atlas database. The topological features of the ceRNA network were then analyzed and the PRAD‑risk lncRNAs were compared with non‑risk lncRNAs within this network. It was revealed that PRAD‑risk lncRNAs had a higher degree, closeness and betweenness centrality, but also had the shortest path length. Finally, 42 significant PRAD‑survival‑associated triplets were identified. Notably, these triplets may form a compacted subnetwork composed of only 25 nodes (5 miRNAs, 4 lncRNAs and 16 genes) and 32 edges, indicating that some nodes were involved in many triplets. Among this subnetwork, mir‑21 indicated the highest degree centrality and was demonstrated to exert its oncogenic effects in prostate tumors by downregulating transforming growth factor β receptor 2 (TGFBR2). Two triplets (MIR22HG_hsa‑mir‑21_TGFBR2 and MIR22HG_hsa‑mir‑21_BCL2) were finally identified; not only were they significantly associated with PRAD survival but they also had the highest average degree in the identified subnetwork. The results from the present study provide further insights into the understanding of the potential roles and interactions of ceRNA triplets and potential prognosis markers for PRAD.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, et al: Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 67:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
3	Kar S, Sengupta D, Deb M, Pradhan N and Patra SK: SOX2 function and Hedgehog signaling pathway are co-conspirators in promoting androgen independent prostate cancer. Biochim Biophys Acta Mol Basis Dis. 1863:253–265. 2017. View Article : Google Scholar : PubMed/NCBI
4	Parnes HL, House MG and Tangrea JA: Prostate cancer prevention: Strategies for agent development. Curr Opin Oncol. 25:242–251. 2013. View Article : Google Scholar : PubMed/NCBI
5	Sun X, Yang Z, Zhang Y, He J, Wang F, Su P, Han J, Song Z and Fei Y: Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer. Int J Clin Exp Pathol. 8:8394–8401. 2015.PubMed/NCBI
6	Das DK, Osborne JR, Lin HY, Park JY and Ogunwobi OO: miR-1207-3p is a novel prognostic biomarker of prostate cancer. Transl Oncol. 9:236–241. 2016. View Article : Google Scholar : PubMed/NCBI
7	Ling CQ, Wang LN, Wang Y, Zhang YH, Yin ZF, Wang M and Ling C: The roles of traditional Chinese medicine in gene therapy. J Integr Med. 12:67–75. 2014. View Article : Google Scholar : PubMed/NCBI
8	Perkel JM: Visiting ‘noncodarnia’. Biotechniques. 54:301, 303–304. 2013. View Article : Google Scholar
9	Schmitt AM and Chang HY: Long noncoding RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
10	Liu K, Yao H, Wen Y, Zhao H, Zhou N, Lei S and Xiong L: Functional role of a long non-coding RNA LIFR-AS1/miR-29a/TNFAIP3 axis in colorectal cancer resistance to pohotodynamictherapy. Biochim Biophys Acta Mol Basis Dis. 1864:2871–2880. 2018. View Article : Google Scholar : PubMed/NCBI
11	Bolha L, Ravnik-Glavac M and Glavac D: Long noncoding RNAs as biomarkers in cancer. Dis Markers. 2017:72439682017. View Article : Google Scholar : PubMed/NCBI
12	Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, et al: APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 52:1089–1095. 2006. View Article : Google Scholar : PubMed/NCBI
13	Yoon JH, Abdelmohsen K and Gorospe M: Functional interactions among microRNAs and long noncoding RNAs. Semin Cell Dev Biol. 34:9–14. 2014. View Article : Google Scholar : PubMed/NCBI
14	Li SQ, Li F, Xiao Y, Wang CM, Tuo L, Hu J, Yang XB, Wang JS, Shi WH, Li X and Cao XF: Comparison of long noncoding RNAs, microRNAs and messenger RNAs involved in initiation and progression of esophageal squamous cell carcinoma. Mol Med Rep. 10:652–662. 2014. View Article : Google Scholar : PubMed/NCBI
15	Thum T and Condorelli G: Long noncoding RNAs and microRNAs in cardiovascular pathophysiology. Circ Res. 116:751–762. 2015. View Article : Google Scholar : PubMed/NCBI
16	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The Rosetta stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
17	Tay Y, Karreth FA and Pandolfi PP: Aberrant ceRNA activity drives lung cancer. Cell Res. 24:259–260. 2014. View Article : Google Scholar : PubMed/NCBI
18	Gu Y, Xiao X and Yang S: LncRNA MALAT1 acts as an oncogene in multiple myeloma through sponging miR-509-5p to modulate FOXP1 expression. Oncotarget. 8:101984–101993. 2017. View Article : Google Scholar : PubMed/NCBI
19	Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Zhang Y, Gorospe M, Prasanth SG, Lal A and Prasanth KV: Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 9:e10033682013. View Article : Google Scholar : PubMed/NCBI
20	Zhang R, Guo Y, Ma Z, Ma G, Xue Q, Li F and Liu L: Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer. Oncotarget. 8:26079–26089. 2017.PubMed/NCBI
21	Samir N, Matboli M, El-Tayeb H, El-Tawdi A, Hassan MK, Waly A, El-Akkad HAE, Ramadan MG, Al-Belkini TN, El-Khamisy S and El-Asmar F: Competing endogenous RNA network crosstalk reveals novel molecular markers in colorectal cancer. J Cell Biochem. 8:6869–6881. 2018. View Article : Google Scholar
22	An Y, Furber K and Ji S: Pseudogenes regulate parental gene expression via ceRNA network. J Cell Mol Med. 21:185–192. 2017. View Article : Google Scholar : PubMed/NCBI
23	Wu H, Wu R, Chen M, Li D, Dai J, Zhang Y, Gao K, Yu J, Hu G, Guo Y, et al: Comprehensive analysis of differentially expressed profiles of lncRNAs and construction of miR-133b mediated ceRNA network in colorectal cancer. Oncotarget. 8:21095–21105. 2017.PubMed/NCBI
24	Giza DE, Vasilescu C and Calin GA: MicroRNAs and ceRNAs: Therapeutic implications of RNA networks. Expert Opin Biol Ther. 14:1285–1293. 2014. View Article : Google Scholar : PubMed/NCBI
25	Cancer Genome Atlas Research Network, . The molecular taxonomy of primary prostate cancer. Cell. 163:1011–1025. 2015. View Article : Google Scholar : PubMed/NCBI
26	Xue D, Lu H, Xu HY, Zhou CX and He XZ: Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12. J Cell Mol Med. 22:3223–3237. 2018. View Article : Google Scholar : PubMed/NCBI
27	Liu Z, Dai J and Shen H: Systematic analysis reveals long noncoding RNAs regulating neighboring transcription factors in human cancers. Biochim Biophys Acta Mol Basis Dis. 9:2785–2792. 2018. View Article : Google Scholar
28	Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, et al: miRTarBase 2016: Updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res. 44:D239–D247. 2016. View Article : Google Scholar : PubMed/NCBI
29	Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K and Kalfakakou D: DIANA-TarBase v7.0: Indexing more than half a million experimentally supported miRNA: mRNA interactions. Nucleic Acids Res. 43((Database Issue)): D153–D159. 2015. View Article : Google Scholar : PubMed/NCBI
30	Betel D, Koppal A, Agius P, Sander C and Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11:R902010. View Article : Google Scholar : PubMed/NCBI
31	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
32	Kertesz M, Iovino N, Unnerstall U, Gaul U and Segal E: The role of site accessibility in microRNA target recognition. Nat Genet. 39:1278–1284. 2007. View Article : Google Scholar : PubMed/NCBI
33	Rehmsmeier M, Steffen P, Hochsmann M and Giegerich R: Fast and effective prediction of microRNA/target duplexes. RNA. 10:1507–1517. 2004. View Article : Google Scholar : PubMed/NCBI
34	Li JH, Liu S, Zhou H, Qu LH and Yang JH: starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42((Database Issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
35	Paraskevopoulou MD, Georgakilas G, Kostoulas N, Reczko M, Maragkakis M, Dalamagas TM and Hatzigeorgiou AG: DIANA-LncBase: Experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res. 41((Database Issue)): D239–D245. 2013. View Article : Google Scholar : PubMed/NCBI
36	Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, Zhang Q, Yan G and Cui Q: LncRNADisease: A database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 41((Database Issue)): D983–D986. 2013.PubMed/NCBI
37	Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B and Wang EW: A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 143:331–336. 2010. View Article : Google Scholar : PubMed/NCBI
38	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
39	Du Z, Sun T, Hacisuleyman E, Fei T, Wang X, Brown M, Rinn JL, Lee MG, Chen Y, Kantoff PW and Liu XS: Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. Nat Commun. 7:109822016. View Article : Google Scholar : PubMed/NCBI
40	Karreth FA and Pandolfi PP: ceRNA cross-talk in cancer: When ce-bling rivalries go awry. Cancer Discov. 3:1113–1121. 2013. View Article : Google Scholar : PubMed/NCBI
41	Chen WJ, Tang RX, He RQ, Li DY, Liang L, Zeng JH, Hu XH, Ma J, Li SK and Chen G: Clinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: A study based on RNA-sequencing and microarray data mining. Oncotarget. 8:61282–61304. 2017.PubMed/NCBI
42	Li DS, Ainiwaer JL, Sheyhiding I, Zhang Z and Zhang LW: Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 20:2285–2295. 2016.PubMed/NCBI
43	Seitz AK, Christensen LL, Christensen E, Faarkrog K, Ostenfeld MS, Hedegaard J, Nordentoft I, Nielsen MM, Palmfeldt J, Thomson M, et al: Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. Sci Rep. 7:3952017. View Article : Google Scholar : PubMed/NCBI
44	Yang Y, Guo JX and Shao ZQ: miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study. Asian Pac J Trop Med. 10:87–91. 2017. View Article : Google Scholar : PubMed/NCBI
45	Shen SJ, Zhang YH, Gu XX, Jiang SJ and Xu LJ: Yangfei Kongliu Formula, a compound Chinese herbal medicine, combined with cisplatin, inhibits growth of lung cancer cells through transforming growth factor-β1 signaling pathway. J Integr Med. 15:242–251. 2017. View Article : Google Scholar : PubMed/NCBI
46	Brattain MG, Markowitz SD and Willson JK: The type II transforming growth factor-beta receptor as a tumor-suppressor gene. Curr Opin Oncol. 8:49–53. 1996. View Article : Google Scholar : PubMed/NCBI
47	Chowdhury S, Ammanamanchi S and Howell GM: Epigenetic targeting of transforming growth factor β receptor II and implications for cancer therapy. Mo Cell Pharmacol. 1:57–70. 2009. View Article : Google Scholar
48	Bonci D and De Maria R: miR-15/miR-16 loss, miR-21 upregulation, or deregulation of their target genes predicts poor prognosis in prostate cancer patients. Mol Cell Oncol. 3:e11097442016. View Article : Google Scholar : PubMed/NCBI
49	Guan Y, Wu Y, Liu Y, Ni J and Nong S: Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy. Prostate. 76:986–993. 2016. View Article : Google Scholar : PubMed/NCBI
50	Mishra S, Deng JJ, Gowda PS, Rao MK, Lin CL, Chen CL, Huang T and Sun LZ: Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene. 33:4097–4106. 2014. View Article : Google Scholar : PubMed/NCBI
51	Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI